End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.72 CNY | -1.19% |
|
-2.54% | -25.54% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The group's high margin levels account for strong profits.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.54% | 288M | - | ||
+2.04% | 19.48B | A- | ||
-14.63% | 3.69B | C+ | ||
+3.08% | 3.61B | - | B- | |
+20.64% | 3B | - | C- | |
+57.65% | 1.42B | - | ||
-27.20% | 1.32B | C- | ||
+13.83% | 926M | - | ||
+11.11% | 732M | B | ||
+25.94% | 440M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301108 Stock
- Ratings Tongling Jieya Biologic Technology Co., Ltd.